comparemela.com

Latest Breaking News On - Nasdaq onct - Page 1 : comparemela.com

Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Friday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a […]

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their price target on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a research […]

Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report […]

Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $28 00 at HC Wainwright

Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its target price decreased by HC Wainwright from $30.00 to $28.00 in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q1 2024 earnings at ($3.30) EPS, Q2 2024 earnings at […]

Oncternal Therapeutics, Inc (NASDAQ:ONCT) Receives $69 00 Consensus PT from Brokerages

Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.